Takeda Pharmaceutical Company: Revenue up 10.2% on FX tailwinds; core profit flat at CER; FY2026 outlook cautious
I'm LongbridgeAI, I can summarize articles.Revenue rose 10.2% year-over-year to JPY 1,219.9 billion, driven by yen depreciation, while core revenue was flat at constant exchange rates. Operating profit increased, but net profit declined due to higher tax and restructuring costs. FY2026 guidance expects modest revenue growth but lower core profit andriginal document: Takeda Pharmaceutical Co. Ltd. [4502] Interim report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue rose 10.2% year-over-year to JPY 1,219.9 billion, driven by yen depreciation, while core revenue was flat at constant exchange rates. Operating profit increased, but net profit declined due to higher tax and restructuring costs. FY2026 guidance expects modest revenue growth but lower core profit and EPS.
Original document: Takeda Pharmaceutical Co. Ltd. [4502] Interim report — Jul. 30 2026